化瘀通络方对糖尿病大鼠肾组织血管内皮生长因子表达的影响

Effect of Huayu Tongluo Formula on the Expression of Vascular Endothelial Growth Factor in Kidney Tissue of Diabetic Rats

目的探讨化瘀通络方对糖尿病大鼠肾脏的保护作用及其对肾组织血管内皮生长因子(VEGF)表达的影响。方法将SD大鼠随机分为正常组(10只)、模型组(8只)、中药组(8只)、西药组(8只),应用链脲佐菌素腹腔注射建立糖尿病模型,中、西药组分别给予化瘀通络方(每日0.904 g/kg)及厄贝沙坦(每日24 mg/kg)干预16周后,测定体重(BW)、右肾指数(RKI)、糖化血红蛋白(HbA1c)、24 h尿蛋白定量(24 h-UTP)、血清白蛋白(ALB)、血肌酐(SCr),光镜和电镜下观察肾组织形态学改变,免疫组化、实时荧光定量PCR法观察肾组织VEGF蛋白及mRNA表达。结果与正常组比较,模型组RKI、HbA1c、24 h-UTP、肾小球基底膜厚度、VEGF表达明显升高,BW、ALB明显降低(P<0.05);与模型组比较,中、西药组RKI、24 h-UTP、肾小球基底膜厚度、VEGF表达明显减少(P>0.05);两治疗组之间比较各指标差异无统计学意义(P>0.05)。结论化瘀通络方可不依赖于血糖控制而延缓早期糖尿病肾病进展,效果与应用厄贝沙坦相似,其机制可能与抑制肾脏血管内皮生长因子的过度表达有关。

Objective To investigate the protective effect of Huayu Tongluo Formula(HYTLF)on the kidney of diabetic rats and the effect on the expression of vascular endothelial growth factor(VEGF)in renal tissue.Methods SD rats were randomly divided into normal group(10 rats),model group(8 rats),Chinese medicine group(8 rats)and Western medicine group(8 rats).Diabetic model was established by intraperitoneal injection of streptozotocin.Chinese and Western medicine groups were given HYTLF(0.904 g/kg daily)and irbesartan(24 mg/kg daily),respectively.After 16 weeks of intervention,body weight(BW),right kidney index(RKI),glycosylated hemoglobin(HbA1c),24-hour urine protein quantity(24h-UTP),serum albumin(ALB),and serum blood creatinine(SCr)were measured.Renal tissue morphology was observed by light and electron microscope.The protein and mRNA expression of VEGF was observed by immunohistochemistry and real-time PCR.Results Compared with the normal group,the RKI,Hb A1c,24h-UTP,glomerular basement membrane thickness,and the expression of VEGF in the model group were significantly increased,while BW and ALB were significantly decreased(P<0.05).Compared with the model group,the RKI,24h-UTP,glomerular basement membrane thickness and the expression of VEGF in the Chinese and Western medicine groups were significantly decreased(P<0.05).There was no significant difference in each index between the two treatment groups(P>0.05).Conclusions HYTLG could delay the progression of early diabetic nephropathy without relying on blood glucose control.Its effect is similar to that of irbesartan,and its mechanism may be related to the inhibition of the over expression of VEGF in renal tissue.